secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2026-10-07T10:11:57+00:00
Accession:  0000885725-26-000064
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Boston Scientific promotes Joe Fitzgerald to COO; creates three segments Jan 1, 2027
--------------------------------------------------------------------------------

- Joseph M. Fitzgerald, 63, EVP and Group President, Cardiovascular, promoted to EVP and COO effective Jan 1, 2027; base salary $1,050,000 and 2027 equity award of $7,000,000.
- Three reportable segments created effective Jan 1, 2027: Interventional Therapies (Lance Bates), Rhythm Solutions (Nick Spadea-Anello), MedSurg (Stephen Morse), each reporting to Fitzgerald.
- Interventional Therapies segment will include the Penumbra business following the anticipated close of that acquisition.
- Mark Bickel, 49, named SVP, Global Accounting Controller and Chief Accounting Officer effective March 1, 2027; Emily Woodworth moves to SVP, Global Finance Controller.
- CEO Mike Mahoney said the new operating model will create greater capacity to focus on long-term growth priorities and let businesses move faster.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000064/0000885725-26-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000064/bsx-20261001.htm
  HTML page:      https://secwatch.observer/filing/0000885725-26-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer